Streetbeat News

Regulatory

AZN

Levi & Korsinsky has initiated an investigation into AstraZeneca PLC for potential securities fraud, following reports of a fraud investigation by Chinese authorities involving senior executives.

Portfolio Pulse from

November 14, 2024 | 10:45 pm

TSLA

Tesla and other electric vehicle stocks fell after reports that President-Elect Donald Trump plans to eliminate the $7,500 EV tax credit.

Portfolio Pulse from

November 14, 2024 | 10:30 pm

OCTO

Eightco Holdings Inc. (NASDAQ: OCTO) reported a net loss of $3.2 million for Q3 2024, an improvement from the previous year's $3.5 million loss, due to better gross margins. Revenues fell to $7.7 million from $23.3 million, impacted by reduced capital for cell phone sales. The company met NASDAQ compliance requirements, ensuring its continued listing.

Portfolio Pulse from

November 14, 2024 | 10:30 pm

AMZN

Amazon faced scrutiny from the House China committee regarding its partnership with TikTok, which allows TikTok users to buy products from Amazon directly through the app. Lawmakers expressed concerns about the safety and wisdom of this collaboration.

Portfolio Pulse from

November 14, 2024 | 10:00 pm

MRNA

PFE

Vaccine-maker stocks, including Moderna and Pfizer, fell after President-elect Donald Trump announced Robert F. Kennedy Jr., a known vaccine skeptic, as his pick to lead the U.S. Department of Health and Human Services.

Portfolio Pulse from

November 14, 2024 | 10:00 pm

XGN

Exagen Inc. has completed validation and regulatory submission for new lupus and rheumatoid arthritis biomarkers on its AVISE® CTD platform, enhancing diagnostic clarity for autoimmune diseases.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

PGEN

Precigen, Inc. reported its Q3 2024 financial results and business updates, highlighting progress in its gene and cell therapy programs. The company completed a pre-BLA meeting with the FDA for PRGN-2012, initiated a confirmatory trial, and is preparing for a potential 2025 launch. Additionally, Precigen is preparing for an end of Phase 1b meeting for PRGN-3006 and presented promising preclinical data for PRGN-3008.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

CKPT

Checkpoint Therapeutics' cosibelimab shows promising results for cSCC treatment. The upcoming PDUFA date on December 28th is crucial for potential FDA approval, which could drive significant market growth despite competitive pressures.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

PSTV

Plus Therapeutics reported its Q3 2024 financial results and highlighted significant business developments, including FDA approval for a Phase 1 trial of Rhenium (186 Re) Obisbemeda for leptomeningeal metastases, positive trial data presentation, and a manufacturing partnership with SpectronRx.

Portfolio Pulse from

November 14, 2024 | 9:30 pm